BofA cuts target for Vertex Pharma stock to USD 667.00
Published on 10/13/2026 at 12:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- BofA lowered its Vertex Pharmaceuticals price target from USD 672.00 to USD 667.00 on October 12, 2026.
- Vertex reported USD 3.33 billion in second-quarter 2026 revenue and USD 1.10 billion in net income.
- Lang & Schwarz quoted Vertex Pharma at EUR 455.98 on October 13, 2026, at 12:09 p.m. CEST.
- Vertex is scheduled to report third-quarter 2026 results on November 2, 2026.
Vertex Pharma (ISIN US92532F1003) was quoted at EUR 455.98 at Lang & Schwarz on October 13, 2026, at 12:09 p.m. CEST. BofA Securities lowered its Vertex Pharmaceuticals price target from USD 672.00 to USD 667.00 on October 12, 2026, while maintaining a Buy rating, Investing.com reports.
What does the kidney program add
The October 12, 2026 BofA note projects third-quarter revenue of USD 2.42 billion for Trikafta, USD 688.00 million for Alyftrek, USD 83.00 million for Casgevy and USD 68.00 million for Journavx, with each figure tied to a separate product forecast. The figures show how Vertex is building a commercial base beyond its established cystic fibrosis franchise.
BofA also expects updates after Vertex completes its acquisition of Crinetics and identified Vertex as a top pick for 2026, according to Investing.com. The lower target shows that the analyst view remains positive while incorporating a more cautious valuation.
Three milestones shape the story
On June 30, 2026, Vertex reported quarterly revenue of USD 3.33 billion and net income of USD 1.10 billion for the second quarter, according to Markets Insider. Revenue increased from USD 2.96 billion in the comparable quarter, while net income rose from USD 1.03 billion.
On September 22, 2026, Vertex announced positive Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease and completion of enrollment in the Phase 2/3 AMPLITUDE trial, MarketScreener reported. On October 12, 2026, BofA cut its target from USD 672.00 to USD 667.00, making the valuation update the latest dated milestone.
Next dates carry hard numbers
Vertex is scheduled to report third-quarter 2026 results on November 2, 2026, and fiscal-year 2026 results on February 9, 2027, according to Barrons. Those dates put the product forecasts and the recently raised fiscal 2026 revenue guidance of USD 13.10 billion to USD 13.20 billion ahead of the next formal results checkpoint.
Trading remains the live reference
The Lang & Schwarz quote placed Vertex Pharma at EUR 455.98 in trading on October 13, 2026, at 12:09 p.m. CEST. The company had a market capitalization of USD 128.7 billion as of October 12, 2026, while Nasdaq data showed a 52-week range of USD 403.16 to USD 560.25.
Market context: Market report S&P 500.
The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.
Vertex Pharma stock facts
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 13, 2026, 12:09 p.m. CEST): EUR 455.98
- Market capitalization: USD 128.7 billion (as of October 12, 2026)
- 52-week range: USD 403.16-560.25 (as of October 12, 2026)
- Sector / Industry: Health care / Biotechnology
- Next earnings date: November 2, 2026
